Talaris Therapeutics Inc Stock

$16.48

0.90% yesterday

Nasdaq, May 20, 09:49 pm CET

ISIN

US87410C1045

Symbol

TRML

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Talaris Therapeutics Inc Stock price

$16.20

-59.31 78.55% 5Y

Nasdaq, Closing price Tue, May 20 2025

-0.43 2.59%

ISIN

US87410C1045

Symbol

TRML

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$416.15m
Enterprise Value	$167.04m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	1.49
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-98.45m
Free Cash Flow (TTM) Free Cash Flow	$-84.04m
Cash position	$249.31m
EPS (TTM) EPS	$-3.22
P/E forward	negative
P/S forward	62.42
EV/Sales forward	25.06
Short interest	13.90%

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Get Started for Free Today

Talaris Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a Talaris Therapeutics Inc forecast:

11x Buy

100%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a Talaris Therapeutics Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Talaris Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	0.04 0.04	92% 92% -
Gross Profit	-0.04 -0.04	- -
- Selling and Administrative Expenses	23 23	19% 19% -
- Research and Development Expense	76 76	219% 219% -
EBITDA	-98 -98	87% 87% -
- Depreciation and Amortization	0.04 0.04	- -
EBIT (Operating Income) EBIT	-98 -98	90% 90% -
Net Profit	-83 -83	73% 73% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Talaris Therapeutics Inc Stock News

Positive

Seeking Alpha

●

about 7 hours ago

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition

Pacibekitug showed statistically significant hs-CRP reduction in CKD patients in the phase 2 TRANQUILITY study, establishing proof-of-concept for IL-6 inhibition. Positive data supports advancing pacibekitug to a phase 3 cardiovascular outcomes trial for ASCVD, pending an FDA meeting in late 2025. The 7 major Atherosclerotic Cardiovascular Disease markets are expected to reach $30.6 billion by ...

Neutral

GlobeNewsWire

●

one day ago

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, will host a conference call and webcast on Tuesday, May 20, 2025 beginning at 8:30 a.m. ET to present topline results from th...

Neutral

GlobeNewsWire

●

19 days ago

Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tourmaline expects to provide further details on the clinical development plan for pacibekitug within cardiovascular inflammation in conjunction with reporting TRANQUILITY topline data – – Cash, cash equival...

More Talaris Therapeutics Inc News

Company Profile

Talaris Therapeutics, Inc. engages in cell therapy. It develops methods of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Its technologies are used to treat inherited metabolic enzyme disorders, red blood cell disorders to induce tolerance to organ transplants, and to treat autoimmune disorders such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and scleroderma. The company was founded by Suzanne Ildstad in 2002 and is headquartered in Louisville, KY.

Head office	United States
CEO	Sandeep Kulkarni
Employees	74
Founded	2021
Website	www.tourmalinebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now